What is Dupixent?
Dupixent is a prescription biologic injection approved by the U.S. Food and Drug Administration (FDA) in 2017 to treat inflammatory skin and respiratory conditions like eczema, asthma, eosinophilic esophagitis, chronic rhinosinusitis with nasal polyps, prurigo nodularis, and chronic obstructive pulmonary disease (COPD). Dupixent is a monoclonal antibody that treats inflammatory conditions by reducing inflammation signals in the immune system.
Dupixent (dupilumab) is jointly manufactured by Sanofi-Aventis LLC and Regeneron Pharmaceuticals, Inc. Since approval, over 800,000 patients have used Dupixent to treat these inflammatory conditions. Recently, many concerns have come to light about Dupixent and the potential risk of developing cutaneous T-cell lymphoma (CTCL).
Pope McGlamry’s defective product attorneys are currently investigating cases where patients took Dupixent and then developed CTCL. If you or a loved one took Dupixent and were diagnosed with CTCL, contact us to discuss your potential case.
What is Cutaneous T-Cell Lymphoma (CTCL)?
CTCL is a rare cancer that affects the lymphatic system. The lymphatic system is part of the body’s germ-fighting system. CTCL is a type of non-Hodgkin lymphoma and there are many subtypes of T-cell lymphomas. T-cell lymphoma starts in white blood cells (leukocytes), which function as a key component of the immune system and protect the body from illness. It often first shows itself as flat, scaly patches on the skin, itchy areas, or thick tumors.
Treatment for CTCL often includes chemotherapy, immunotherapy, radiation therapy, targeted therapy, clinical trials, and bone marrow stem cell transplant.
Understanding the Link Between Dupixent and Lymphoma Injuries
There have been numerous case studies linking patients’ use of Dupixent to T-Cell Lymphoma since the drug came to market in Spring 2017. Studies have shown that Dupixent alters the immune system pathways, potentially contributing to the development of CTCL and/or accelerating existing, undiagnosed Lymphoma.
As early as 2020, doctors and researchers began studying the relationship between the two, determining that use of Dupixent exacerbated the development of T-cell Lymphoma in patients. According to a 2024 study published in the Journal of the American Academy of Dermatology, Dupixent users being treated for atopic dermatitis had approximately four-times greater risk of developing CTCL. A second study published in Dermatologic Therapy also reported an increased risk of CTCL among patients using Dupixent, and where the majority of patients diagnosed with CTCL were diagnosed within the first year following Dupixent use.
What Should I Do If I’m Taking Dupixent?
If you have been prescribed Dupixent, do not stop taking it without first talking to your doctor. If you have concerns, schedule a time to speak with your healthcare provider and decide what the best option for you is.
If you start to develop new or unusual symptoms while taking Dupixent, you should contact your healthcare provider right away. Make note of your symptoms- when they start, what they are, and any medical treatment or evaluations you receive. This information could be important if you decide at some point to pursue legal action.
Lawsuits Against the Makers of Dupixent
As awareness has increased about the connection between Dupixent and T-cell Lymphoma, some people have started filing lawsuits against manufacturers Sanofi-Aventis and Regeneron Pharmaceuticals. These lawsuits are based on the idea that the manufacturers knew about the risk of Dupixent causing or accelerating T-cell Lymphoma, and failed to adequately warn doctors and patients about the risk.
What Should You Do If You Took Dupixent and Were Diagnosed with Lymphoma?
If you or someone you know took Dupixent and were diagnosed with T-Cell lymphoma or other severe adverse effects, you may be eligible for compensation. Compensation may include medical expenses, pain and suffering, as well as financial remuneration for any loss of earnings and future loss of income.
Pope McGlamry’s team has significant experience handling pharmaceutical products liability litigation. Contact our experienced attorneys by phone at (404)-523-7706 for a free and confidential consultation, or submit your case evaluation online.
